FT-538

N/A

Report date: 2022/09/06 18:03:04

Base Information

Drug NameFT-538
Drug Alias NameFT-538
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsLow affinity immunoglobulin gamma Fc region receptor III-A agonists
TargetsLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursRespiratory Distress Syndrome, Adult +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota
Inactive CompaniesFate Therapeutics Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultLeukemia, Monocytic, Acute +[5] 
Inactive IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A